INVA (INVA)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 5/9, Altman Z 3.9. Beneish M-Score of -1.96 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe company demonstrates robust capital efficiency, evidenced by a 17.1% ROIC that significantly outpaces the 7.5% WACC to generate a +9.7% spread, indicating strong value creation potential relative to its cost of capital. This high return is underpinned by exceptional profitability metrics, with an 81.2% gross margin and a staggering 65.9% net margin driving earnings quality, while revenue expands at a healthy 14.7% year-over-year rate. Financial stability appears solid given the Altman Z-Score of 3.9, which suggests a low probability of bankruptcy, yet the Piotroski F-Score of 5/9 indicates moderate fundamental strength rather than peak financial health. Furthermore, the Beneish M-Score of -1.96 points to earnings that are highly unlikely to be manipulated, reinforcing confidence in the reported margin expansion and growth trajectory.
Valuation metrics present a compelling divergence between current pricing and intrinsic value estimates. Trading at a 6.9x P/E multiple, the stock appears significantly compressed relative to its historical performance and sector peers who typically command higher multiples for companies with such superior margins and double-digit revenue growth. The disparity is further highlighted by the DCF fair value of $56, implying that current market prices are pricing in negligible future growth or excessive downside risk rather than accounting for the 14.7% organic expansion and high capital returns currently being delivered. This suggests the market may be undervaluing the business's ability to sustain its margin profile and reinvest at rates exceeding its cost of equity.
While specific risk factor deltas, insider activity data, or Fama-French alpha figures were not provided in the input parameters, the existing fundamental profile presents a distinct asymmetric setup where high-quality earnings generation meets depressed valuation multiples. The combination of low manipulation scores, strong cash flow conversion implied by net margins, and significant upside to fair value creates an environment where traditional risk-reward models might favor long-term accumulation over short-term volatility concerns.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 6% | 7.5% | 9.5% |
|---|---|---|---|
| 2% | $64 | $48 | $36 |
| 3% | $81 | $56 | $40 |
| 4% | $115 | $68 | $45 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=7.5%, terminal growth 3%. Fair value $56 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XPH or VFMV, the fund manager is mechanically forced to buy or sell INVA shares regardless of INVA's individual fundamentals. We estimate $35M of passive capital is structurally linked to INVA through 8 tracked ETFs. Passive flows have a limited but growing influence on INVA's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in INVA to visualize passive redemption contagion across ETFs and collateral stocks.
If INVA (INVA) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies CORCEPT THERAPEUTICS INC (CORT) as the most exposed collateral stock, sharing 3 ETFs with INVA. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 8 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
INVA Ownership Dynamics
ETFs with Highest INVA Exposure
Float lock-up computed from 8 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
INVA Capital Efficiency
How efficiently does INVA convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
INVA converts 50% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. The positive ROIC-WACC spread of 9.7% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-04-17 | 3 | $23.60 | $70.8 |
| 2026-04-16 | 123 | $23.92 | $2,942.16 |
| 2026-04-15 | 4,044 | $24.19 | $97,824.36 |
| 2026-04-14 | 142 | $23.97 | $3,403.74 |
| 2026-04-07 | 3 | $23.02 | $69.06 |
| 2026-03-31 | 438 | $22.91 | $10,034.58 |
| 2026-03-23 | 76 | $21.70 | $1,649.2 |
| 2026-03-17 | 319 | $22.15 | $7,065.85 |
| 2026-03-10 | 3,921 | $22.32 | $87,516.72 |
| 2026-02-26 | 4,519 | $24.24 | $109,540.56 |
| 2026-02-17 | 38 | $22.70 | $862.6 |
| 2026-02-10 | 73 | $21.63 | $1,578.99 |
| 2026-02-04 | 50 | $21.00 | $1,050 |
| 2026-01-02 | 683 | $19.99 | $13,653.17 |
| 2025-12-30 | 49 | $19.72 | $966.28 |
| 2025-12-24 | 18,904 | $19.51 | $368,817.04 |
| 2025-12-22 | 411 | $19.99 | $8,215.89 |
| 2025-12-11 | 183 | $20.62 | $3,773.46 |
| 2025-12-10 | 20,604 | $20.71 | $426,708.84 |
| 2025-12-01 | 118 | $21.73 | $2,564.14 |
| 2025-11-10 | 1,577 | $20.86 | $32,896.22 |
| 2025-11-05 | 109 | $18.15 | $1,978.35 |
| 2025-11-04 | 20 | $18.11 | $362.2 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare INVA to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.